Literature DB >> 32488760

GH deficiency in cancer survivors in the transition age: diagnosis and therapy.

Emilia Sbardella1, Marco Crocco2, Tiziana Feola3, Fortuna Papa4, Giulia Puliani3, Daniele Gianfrilli3, Andrea M Isidori3, Ashley B Grossman5,6.   

Abstract

BACKGROUND: Survival rates among childhood cancer survivors (CCSs) have significantly risen in the last 40 years due to substantial improvements in treatment protocols. However, this improvement has brought with it serious late effects that frequently involve the endocrine system. Of the endocrine disorders, GH deficiency (GHD) is the most common among CCSs as a consequence of a history of cancers, surgery, and/or radiotherapy involving the hypothalamo-pituitary region.
METHODS: A comprehensive search of English language articles regardless of age was conducted in the MEDLINE database between December 2018 and October 2019. We selected all studies on GH therapy in CCSs during the transition age regarding the most challenging topics: when to retest; which diagnostic tests and cut-offs to use; when to start GH replacement therapy (GHRT); what GH dose to use; safety; quality of life, compliance and adherence to GHRT; interactions between GH and other hormonal replacement treatments.
RESULTS: In the present review, we provide an overview of the current clinical management of challenges in GHD in cancer survivors in the transition age.
CONCLUSIONS: Endocrine dysfunction among CCSs has a high prevalence in the transition age and increase with time. Many endocrine disorders, including GHD, are often not diagnosed or under-diagnosed, probably due to the lack of specialized centers for the long-term follow-up. Therefore, it is crucial that transition specialized clinics should be increased in terms of number and specific skills in order to manage endocrine disorders in adolescence, a delicate and complex period of life. A multidisciplinary approach, also including psychological counseling, is essential in the follow-up and management of these patients in order to minimize their disabilities and maximize their quality of life.

Entities:  

Keywords:  Adolescence; Cancer; Growth hormone; Survivor; Transition

Mesh:

Substances:

Year:  2020        PMID: 32488760     DOI: 10.1007/s11102-020-01052-0

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  3 in total

1.  Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study.

Authors:  T Feola; R Sa Pirchio; G Puliani; R Pofi; M Crocco; V Sada; F Sesti; F Verdecchia; D Gianfrilli; M Appetecchia; N Di Iorgi; M L Jaffrain-Rea; R Pivonello; A M Isidori; A B Grossman; E Sbardella
Journal:  J Endocrinol Invest       Date:  2022-08-24       Impact factor: 5.467

2.  Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.

Authors:  Manuela Cerbone; Harshini Katugampola; Helen L Simpson; Mehul T Dattani
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

Review 3.  Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature.

Authors:  Matteo Spaziani; Chiara Tarantino; Natascia Tahani; Daniele Gianfrilli; Emilia Sbardella; Andrea M Isidori; Andrea Lenzi; Antonio F Radicioni
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.